Replies to post #53225 on Cytodyn Inc (CYDY)

[Saltz]

That’s a very aggressive outlook. IMO the likelihood of 32 partnerships is a pipe dream at this point in time with 2-4 patients on product in TNBC. I think your a little ahead of the ball. We are just North of $1. Let’s advance the science and uplist first.

[Bobbyinvest]

Lol, 32 partnerships? That would be a nightmare to manage. Great imagination though. Let’s get above $2 or so dollars first and HIV approved and revenues flowing before we get this ambitious. Cancer is still in the beginning stages and we need more than 4 patients to establish the data FDA would require. Still I think it would take 2020-2021 to play out, millions needed in CAP EX to generate the necessary data.

[Amatuer17]

None of the indications are proven - the minute basket trial is approved and NP starts spilling beans about efficacy and it is verifiable - this will go under buyout.
It will not remain for 32 indication testing.

If they can prove efficacy against metastasis for mTNBC in larger number of patients, some BP will pull the trigger.

2020 has started slow in M&A area - JPM conf did not yield any news - BP are hungry with new treatment - they can go after cancer and sell HIV portion for royalty to GILD or VIIV.
Look at GILD report card yesterday - they may be too hungry and pull the trigger if results from 4-10 patients show high efficacy.

[newrunner]

Venus1 you are so right! Nadar has a plan and it's not a buyout.....it will be about 32 partnerships.....

1. HIV cash and 50%

2. Breast Cancer Cash +50%

3. Colon Cancer cash + 50%


4. CytoDyn announced it will begin 8 pre-clinical studies on melanoma cancer, pancreatic, breast, prostate, colon, lung, liver, and stomach cancer.

$500.00 a share is not crazy!